| The use of recombinant human activated protein C (rhAPC) in the treatment of severe sepsis in immunosuppressed patients in the course of hematological diseases. | |
| | |
MedLine Citation:
|
PMID: 16049385 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Treatment of hemopoietic system neoplasias involves severe complications associated with immunosuppression. We present two cases of treating severe sepsis utilizing recombinant human activated protein C (rhAPC) in the course of bilateral pneumonia in patients with hairy cell leukemia (HCL) and T-cell acute lymphoblastic leukemia (ALL). RhAPC, limited the coagulation cascade by inactivating FVa and FVIIIa, directly and indirectly limiting systemic inflammatory response syndrome (SIRS), and improved the fibrinolysis process. These actions break the pathomechanism of sepsis and improve survival. CASE REPORT: Besides intensive, multidirectional treatment of severe sepsis, Xigris (activated drotrecogin alfa) was administered on the second day in both cases. The infusion continued, as recommended, for 96 hours without complications. During treatment the patients' general condition and respiratory efficiency improved, allowing respirator weaning on days 5 and 8 of therapy. These cases of severe sepsis and immunosuppression indicate a high therapeutic efficacy of drotrecogin alfa (activated). Treatment outcome was uncertain because of the patients' hematological condition, so rapid restoration of respiratory efficiency and no disease progression after discontinuing treatment was a great success, possibly due to implementing Xigris at a relatively early stage of sepsis and the intensive therapy conducted according to Surviving Sepsis Campaign guidelines. CONCLUSIONS: Patient survival in severe sepsis directly depends on early diagnosis and institution of treatment. 1. These cases confirm the effectiveness of drotrecogin alfa in severe sepsis as part of multidirectional therapy. 2. Microorganisms causing atypical pneumonia should be considered in diagnosing infections in patients treated with cytostatic agents. |
| | |
Authors:
|
Anna Kunsdorf-Wnuk; Ewa Marzec-Lewenstein; Danuta Arct-Danielak; Ewa Musioł; Romuald Bohatyrewicz; Rafał Becht |
Related Documents
:
|
11057795 - Effect of dopexamine on outcome after major abdominal surgery: a prospective, randomize... 7802525 - Improving long-term prognosis for survivors of mechanical ventilation in patients with ... 3563425 - Multivariate prognostication in bacterial meningitis of childhood. 12911185 - Surgical cricothyroidotomy in trauma patients. 10876205 - Revascularization of the superior mesenteric artery alone for treatment of intestinal i... 20394255 - Dexamethasone with either granisetron or ondansetron for postoperative nausea and vomit... |
Publication Detail:
|
Type: Case Reports; Journal Article Date: 2005-07-25 |
Journal Detail:
|
Title: Medical science monitor : international medical journal of experimental and clinical research Volume: 11 ISSN: 1234-1010 ISO Abbreviation: Med. Sci. Monit. Publication Date: 2005 Aug |
Date Detail:
|
Created Date: 2005-08-29 Completed Date: 2005-09-23 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 9609063 Medline TA: Med Sci Monit Country: Poland |
Other Details:
|
Languages: eng Pagination: CS49-55 Citation Subset: IM |
Affiliation:
|
Department of Anesthesiology and Intensive Care, Silesian Medical University, Katowice, Poland. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Enzyme Activation Humans Immune Tolerance* Leukemia, Hairy Cell / complications*, immunology, therapy Male Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications*, immunology, therapy Protein C / therapeutic use* Recombinant Proteins / therapeutic use Sepsis / complications*, drug therapy* |
| Chemical | |
Reg. No./Substance:
|
0/Protein C; 0/Recombinant Proteins |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Clinical and morphological diagnosis of cardiac AL amyloidosis: a review of findings and difficultie...
Next Document: Endocannabinoid signaling in stress, medicine and wellness.